Ubs Group Ag Leap Therapeutics, Inc. Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023
BUY
$0.29 - $0.72 $888 - $2,206
3,064 Added 30.64%
13,064 $4,000
Q4 2022

Feb 08, 2023
BUY
$0.42 - $9.18 $4,200 - $91,800
10,000 New
10,000 $4,000
Q2 2022

Aug 10, 2022
SELL
$0.96 - $1.91 $13,718 - $27,293
-14,290 Reduced 95.72%
639 $1,000
Q1 2022

May 16, 2022
BUY
$1.6 - $3.35 $8,060 - $16,877
5,038 Added 50.94%
14,929 $26,000
Q4 2021

Feb 14, 2022
SELL
$2.08 - $3.65 $7,537 - $13,227
-3,624 Reduced 26.81%
9,891 $32,000
Q3 2021

Nov 15, 2021
BUY
$1.35 - $4.01 $8,795 - $26,125
6,515 Added 93.07%
13,515 $54,000
Q1 2021

May 12, 2021
BUY
$1.82 - $3.01 $4,497 - $7,437
2,471 Added 54.56%
7,000 $13,000
Q4 2020

Feb 11, 2021
BUY
$1.49 - $2.37 $3,768 - $5,993
2,529 Added 126.45%
4,529 $11,000
Q3 2020

Nov 12, 2020
BUY
$1.68 - $2.17 $3,360 - $4,340
2,000 New
2,000 $4,000
Q4 2019

Feb 14, 2020
SELL
$0.63 - $1.37 $1,775 - $3,860
-2,818 Closed
0 $0
Q3 2019

Nov 14, 2019
BUY
$1.17 - $2.36 $3,297 - $6,650
2,818 New
2,818 $3,000
Q2 2019

Aug 14, 2019
SELL
$1.36 - $2.07 $2,133 - $3,247
-1,569 Closed
0 $0
Q1 2019

May 14, 2019
BUY
$1.39 - $3.07 $2,180 - $4,816
1,569 New
1,569 $3,000
Q4 2018

Feb 14, 2019
SELL
$1.92 - $7.94 $3,360 - $13,895
-1,750 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$6.52 - $9.13 $2,842 - $3,980
436 Added 33.18%
1,750 $14,000
Q2 2018

Aug 14, 2018
SELL
$6.76 - $10.01 $4,116 - $6,096
-609 Reduced 31.67%
1,314 $12,000
Q1 2018

May 15, 2018
SELL
$6.06 - $8.54 $1,733 - $2,442
-286 Reduced 12.95%
1,923 $16,000
Q4 2017

Feb 14, 2018
BUY
$4.99 - $7.3 $5,089 - $7,446
1,020 Added 85.79%
2,209 $14,000
Q3 2017

Nov 14, 2017
BUY
$5.15 - $7.14 $6,123 - $8,489
1,189
1,189 $7,000

Others Institutions Holding LPTX

# of Institutions
1
Shares Held
265K
Call Options Held
0
Put Options Held
0
View Full List

About LEAP THERAPEUTICS, INC.

LPTX Quotes by TradingView
  • Ticker LPTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,021,400
  • Market Cap $275M
  • Description
  • Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...
More about LPTX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email